Dengue viruses – an overview

References

• Westaway EG, Brinton MA, Gaidamovich S, Horzinek MC, Igarashi A, Kaariainen L, etal. Flaviviridae. Intervirology. 1985; 24: 183–92.
   PubMed Web of Science ®Google Scholar
• Wang E, Ni H, Xu R, Barrett AD, Watowich SJ, Gubler DJ, etal. Evolutionary relationships of endemic/ epidemic and sylvatic dengue viruses. J Virol. 2000; 74: 3227–34.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G. Dengue: an update. Lancet Infect Dis. 2002; 2: 33–42.
   PubMed Web of Science ®Google Scholar
• WHO. Dengue haemorrhagic fever. Diagnosis, treatment, prevention and control. 1997; Geneva: WHO. 12–23.
   Google Scholar
• Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002; 10: 100–3.
   PubMedGoogle Scholar
• WHO. Dengue: guidelines for diagnosis, treatment, prevention and control – New ed. 2009; Geneva: World Health Organization.
   Google Scholar
• Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev. 1990; 3: 376–96.
   PubMed Web of Science ®Google Scholar
• Rush B, Garrison-Morton. An account of the bilious remitting fever, as it appeared in Philadelphia in the summer and autumn of the year 1780. Medical inquiries and observations . 1789; Philadelphia: Pritchard & Hall. 104.
   Google Scholar
• Tsai CJ, Kuo CH, Chen PC, Changcheng CS. Upper gastrointestinal bleeding in dengue fever. Am J Gastroenterol. 1991; 86: 33–5.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Strickman D, Vaughn DW. Dengue epidemiology: virus epidemiology, ecology, and emergence. Adv Virus Res. 2003; 61: 235–89.
   PubMedGoogle Scholar
• Tun-Lin W, Burkot TR, Kay BH. Effects of temperature and larval diet on development rates and survival of the dengue vector Aedes aegypti in north Queensland, Australia. Med Vet Entomol. 2000; 14: 31–7.
   PubMed Web of Science ®Google Scholar
• Ooi E-E, Gubler DJ, Hanley KA, Weaver SC. Dengue virus-mosquito interactions. Frontiers in dengue virus research. 2010; Norfolk, UK: Caister Academic Press. 143–56.
   Google Scholar
• Singh KR, Paul SD. Isolation of dengue viruses in Aedes albopictus cell cultures. Bull World Health Organ. 1969; 40: 982–3.
   Web of Science ®Google Scholar
• Pavri KM, Ghosh SN. Complement-fixation tests for simultaneous isolation and identification of dengue viruses, using tissue cultures. Bull World Health Organ. 1969; 40: 984–6.
   Web of Science ®Google Scholar
• Stalder J, Reigel F, Flaviano A, Koblet H. Infection of the Aedes albopictus cell clone C6/36 with Semliki Forest virus. Experientia. 1981; 37: 1229.
   Google Scholar
• McCall P, Kittayapong P. Control of dengue vectors: tools and strategies. Report of the ScientificWorking Group on Dengue. 2006; Geneva:World Health Organization. (TDR/SWG/08).
   Google Scholar
• McCall PJ, Lenhart A. Dengue control. Lancet Infect Dis. 2008; 8: 7–9.
   Web of Science ®Google Scholar
• Pang X, Zhang M, Dayton AI. Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV. BMC Microbiol. 2001; 1: 28.
   Google Scholar
• Pang X, Zhang M, Dayton AI. Development of Dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiol. 2001; 1: 18.
   PubMedGoogle Scholar
• Alvarez DE, Lodeiro MF, Filomatori CV, Fucito S, Mondotte JA, Gamarnik AV. Structural and functional analysis of dengue virus RNA. Novartis Found Symp. 2006; 277: 120–32. discussion 132–5, 251–3.
   Google Scholar
• Gamarnik A, Hanley KA, Weaver SC. Role of the dengue virus 5’ and 3’ untranslated regions in viral replication. Frontiers in dengue virus research. 2010; Norfolk, UK: Caister Academic Press. 55–78.
   Google Scholar
• Padmanabhan R, Strongin AY, Hanley KA, Weaver SC. Translation and processing of the dengue virus polyprotein. Frontiers in dengue virus research. 2010; Norfolk, UK: Caister Academic Press. 13–34.
   Google Scholar
• Yu L, Nomaguchi M, Padmanabhan R, Markoff L. Specific requirements for elements of the 5’ and 3’ terminal regions in flavivirus RNA synthesis and viral replication. Virology. 2008; 374: 170–85.
   PubMed Web of Science ®Google Scholar
• Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, etal. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 1997; 3: 866–71.
   PubMed Web of Science ®Google Scholar
• Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, etal. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med. 2003; 197: 823–9.
   PubMed Web of Science ®Google Scholar
• Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 2008; 4: e17.
   PubMed Web of Science ®Google Scholar
• Chen ST. Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY, et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature. 2008; 453: 672–6.
   PubMed Web of Science ®Google Scholar
• Watson AA, Lebedev AA, Hall BA, Fenton-May AE, Vagin AA, Dejnirattisai W, etal. Structural flexibility of the macrophage dengue virus receptor CLEC5A: implications for ligand binding and signaling. J Biol Chem. 2011; 286: 24208–24218.
   Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004; 427: 313–9.
   PubMed Web of Science ®Google Scholar
• Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature. 1995; 375: 291–8.
   PubMed Web of Science ®Google Scholar
• Heinz FX, Allison SL. Flavivirus structure and membrane fusion. Adv Virus Res. 2003; 59: 63–97.
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Guirakhoo F, Roehrig JT. The envelope glycoproteins of dengue 1 and dengue 2 viruses grown in mosquito cells differ in their utilization of potential glycosylation sites. Virology. 1994; 203: 241–9.
   PubMed Web of Science ®Google Scholar
• Lee E, Weir RC, Dalgarno L. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology. 1997; 232: 281–90.
   Web of Science ®Google Scholar
• Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, Virelizier JL, etal. Dendritic-cell-specific ICAM3- grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 2003; 4: 723–8.
   PubMed Web of Science ®Google Scholar
• Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol. 2006; 80: 11418–31.
   PubMed Web of Science ®Google Scholar
• Mackenzie JM, Jones MK, Young PR. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology. 1996; 220: 232–40.
   PubMed Web of Science ®Google Scholar
• Miller S, Sparacio S, Bartenschlager R. Subcellular localization and membrane topology of the dengue virus type 2 Non-structural protein 4B. J Biol Chem. 2006; 281: 8854–63.
   PubMed Web of Science ®Google Scholar
• Salonen A, Ahola T, Kaariainen L. Viral RNA replication in association with cellular membranes. Curr Top Microbiol Immunol. 2005; 285: 139–73.
   PubMed Web of Science ®Google Scholar
• Lobigs M. Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3. Proc Natl Acad Sci U S A. 1993; 90: 6218–22.
   PubMed Web of Science ®Google Scholar
• Yamshchikov VF, Compans RW. Regulation of the late events in flavivirus protein processing and maturation. Virology. 1993; 192: 38–51.
   Web of Science ®Google Scholar
• Pethel M, Falgout B, Lai CJ. Mutational analysis of the octapeptide sequence motif at the NS1-NS2A cleavage junction of dengue type 4 virus. J Virol. 1992; 66: 7225–31.
   Web of Science ®Google Scholar
• Bazan JF, Fletterick RJ. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology. 1989; 171: 637–9.
   PubMed Web of Science ®Google Scholar
• Miller S, Romero-Brey I, Bartenschlager R, Hanley KA, Weaver SC. The dengue virus replication complex. Frontiers in dengue virus research. 2010; Norfolk, UK: Caister Academic Press. 35–54.
   Google Scholar
• Preugschat F, Strauss JH. Processing of nonstructural proteins NS4A and NS4B of dengue 2 virus in vitro and in vivo. Virology. 1991; 185: 689–97.
   Web of Science ®Google Scholar
• Winkler G, Maxwell SE, Ruemmler C, Stollar V. Newly synthesized dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane- associated after dimerization. Virology. 1989; 171: 302–5.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, etal. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis. 2002; 186: 1165–8.
   PubMed Web of Science ®Google Scholar
• Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S, Diamond MS, etal. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med. 2010; 207: 793–_806.
   PubMed Web of Science ®Google Scholar
• Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol. 1987; 68: 853–7.
   PubMed Web of Science ®Google Scholar
• Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS. Autoimmune pathogenesis in dengue virus infection. Viral Immunol. 2006; 19: 127–32.
   Web of Science ®Google Scholar
• Stadler K, Allison SL, Schalich J, Heinz FX. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol. 1997; 71: 8475–81.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Heinz FX, Mandl CW, Holzmann H, Kunz C. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J Gen Virol. 1991; 72: 1323–9.
   Web of Science ®Google Scholar
• Guirakhoo F, Bolin RA, Roehrig JT. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology. 1992; 191: 921–31.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, etal. Structures of immature flavivirus particles. EMBO J. 2003; 22: 2604–13.
   PubMed Web of Science ®Google Scholar
• Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV, etal. Dengue and dengue haemorrhagic fever. Lancet. 1998; 352: 971–7.
   PubMed Web of Science ®Google Scholar
• WHO. Prevention and control of dengue and dengue haemorrhagic fever. Comprehensive Guidelines. 1999; New Delhi: World Health Organization, Regional Publication. Vol. 29.
   Google Scholar
• Schwartz E, Mileguir F, Grossman Z, Mendelson E. Evaluation of ELISA-based sero-diagnosis of dengue fever in travelers. J Clin Virol. 2000; 19: 169–73.
   PubMed Web of Science ®Google Scholar
• Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, etal. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis. 2006; 43: 1023–30.
   PubMed Web of Science ®Google Scholar
• Hang VT, Nguyet NM, Trung DT, Tricou V, Yoksan S, Dung NM. Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoS Negl Trop Dis. 2009; 3: e360.
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, etal. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000; 181: 2–9.
   PubMed Web of Science ®Google Scholar
• Young PR, Hilditch PA, Bletchly C, Halloran W. An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol. 2000; 38: 1053–7.
   PubMed Web of Science ®Google Scholar
• Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M. Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol. 2002; 40: 376–81.
   PubMed Web of Science ®Google Scholar
• Lapphra K, Sangcharaswichai A, Chokephaibulkit K, Tiengrim S, Piriyakarnsakul W, Chakorn T, etal. Evaluation of an NS1 antigen detection for diagnosis of acute dengue infection in patients with acute febrile illness. Diagn Microbiol Infect Dis. 2008; 60: 387–91.
   Web of Science ®Google Scholar
• Schilling S, Ludolfs D, Van An L, Schmitz H. Laboratory diagnosis of primary and secondary dengue infection. J Clin Virol. 2004; 31: 179–84.
   PubMed Web of Science ®Google Scholar
• Dussart P, Petit L, Labeau B, Bremand L, Leduc A, Moua D. Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. PLoS Negl Trop Dis. 2008; 2: e280.
   Web of Science ®Google Scholar
• Phuong HL, Thai KT, Nga TT, Giao PT, Hung le Q, Binh TQ, etal. Detection of dengue nonstructural 1 (NS1) protein in Vietnamese patients with fever. Diagn Microbiol Infect Dis. 2009; 63: 372–8.
   Web of Science ®Google Scholar
• Duong V, Ly S, Lorn Try P, Tuiskunen A, Ong S, Chroeung N. Clinical and virological factors influencing the performance of a NS1 antigen-capture assay and potential use as a marker of dengue disease severity. PLoS Negl Trop Dis. 2011; 5: e1244.
   PubMed Web of Science ®Google Scholar
• Gibbons RV, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, etal. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg. 2007; 77: 910–3.
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, etal. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology. 2006; 353: 166–73.
   PubMed Web of Science ®Google Scholar
• Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine. 2006; 24: 2200–7.
   PubMed Web of Science ®Google Scholar
• Wisseman CL Jr, Sweet BH, Rosenzweig EC, Eylar OR. Attenuated living type I dengue vaccines. Am J Trop Med Hyg. 1963; 12: 620–3.
   Web of Science ®Google Scholar
• Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, etal. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever preimmunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006; 2: 60–7.
   PubMed Web of Science ®Google Scholar
• Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, etal. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg. 2003; 69(6 Suppl): 17–23.
   Web of Science ®Google Scholar
• Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, etal. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002; 66: 264–72.
   PubMed Web of Science ®Google Scholar
• Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, etal. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis. 1994; 170: 1448–55.
   PubMed Web of Science ®Google Scholar
• Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg. 2003; 69(6 Suppl): 24–31.
   PubMed Web of Science ®Google Scholar
• Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3’ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol. 1996; 70: 3930–7.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, etal. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001; 75: 7290–304.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS. Next-generation dengue vaccines: novel strategies currently under development. Viruses. 2011; 3: 1800–14.
   Web of Science ®Google Scholar
• Gubler DJ. The global pandemic of dengue/dengue haemorrhagic fever: current status and prospects for the future. Ann Acad Med Singap. 1998; 27: 227–34.
   PubMedGoogle Scholar
• Halstead SB, Deen J. The future of dengue vaccines. Lancet. 2002; 360: 1243–5.
   PubMed Web of Science ®Google Scholar
• Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, etal. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005; 353: 877–89.
   PubMed Web of Science ®Google Scholar
• LaBauve ME, Kuhn RJ, Hanley KA, Weaver SC. Novel therapeutic approaches for dengue disease. Frontiers in dengue virus research. 2010; Norfolk, UK: Caister Academic Press. 239–64.
   Google Scholar
• Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998; 11: 480–96.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis. 2002; 6: 118–24.
   PubMedGoogle Scholar
• Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica. 2002; 11: 223–7.
   PubMedGoogle Scholar
• Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, Sun W, etal. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg. 2001; 65: 180–3.
   PubMed Web of Science ®Google Scholar
• Balmaseda A, Hammond SN, Perez L, Tellez Y, Saborio SI, Mercado JC, etal. Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg. 2006; 74: 449–_56.
   PubMed Web of Science ®Google Scholar
• Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis. 2003; 9: 800–9.
   PubMed Web of Science ®Google Scholar
• Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, etal. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology. 1997; 230: 244–51.
   PubMed Web of Science ®Google Scholar
• Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg. 1988; 38: 172–80.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med. 1970; 42: 311–28.
   PubMed Web of Science ®Google Scholar
• Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, etal. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The outbreak 1980. Am J Epidemiol. 1984; 120: 653–69.
   PubMed Web of Science ®Google Scholar
• Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, etal. Risk factors in dengue shock syndrome. Am J Trop Med Hyg. 1997; 56: 566–72.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Sierra B, Kouri G, Farrar J, Simmons C, Hanley KA, Weaver SC. Host and virus determinants of susceptibility and dengue disease severity. Frontiers in dengue virus research. 2010; Norfolk, UK: Caister Academic Press. 79–102.
   Google Scholar
• Bravo JR, Guzman MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg. 1987; 81: 816–20.
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Donnelly CA, Anderson RM. Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys. Philos Trans R Soc Lond B Biol Sci. 1999; 354: 757–68.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, etal. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010; 328: 745–8.
   PubMed Web of Science ®Google Scholar
• Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, etal. Immature dengue virus: a veiled pathogen?. PLoS Pathog. 2010; 6: e1000718.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S, etal. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007; 13: 282–6.
   PubMed Web of Science ®Google Scholar
• Chau TN, Hieu NT, Anders KL, Wolbers M, Lien le B, Hieu LT, etal. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis. 2009; 200: 1893–900.
   PubMed Web of Science ®Google Scholar
• Pengsaa K, Luxemburger C, Sabchareon A, Limkittikul K, Yoksan S, Chambonneau L, etal. Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis. 2006; 194: 1570–6.
   PubMed Web of Science ®Google Scholar
• Azeredo EL, Zagne SM, Santiago MA, Gouvea AS, Santana AA, Neves-Souza PC, etal. Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology. 2001; 204: 494–507.
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Kumaria R. Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. Indian J Med Res. 2006; 123: 25–30.
   Web of Science ®Google Scholar
• Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, etal. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis. 2004; 189: 221–32.
   PubMed Web of Science ®Google Scholar
• Mustafa AS, Elbishbishi EA, Agarwal R, Chaturvedi UC. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol. 2001; 30: 229–33.
   Google Scholar
• Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, Cabrera MV, etal. IL-10 levels in dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol. 2004; 73: 230–4.
   Web of Science ®Google Scholar
• Pinto LM, Oliveira SA, Braga EL, Nogueira RM, Kubelka CF. Increased pro-inflammatory cytokines (TNF-alpha and IL-6) and anti-inflammatory compounds (sTNFRp55 and sTNFR p75) in Brazilian patients during exanthematic dengue fever. Mem Inst Oswaldo Cruz. 1999; 94: 387–94.
   Web of Science ®Google Scholar
• Yang KD, Wang CL, Shaio MF. Production of cytokines and platelet activating factor in secondary dengue virus infections. J Infect Dis. 1995; 172: 604–5.
   Web of Science ®Google Scholar
• Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, etal. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis. 2002; 185: 1213–21.
   PubMed Web of Science ®Google Scholar
• Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, etal. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology. 2003; 305: 330–8.
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, etal. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis. 1997; 176: 322–30.
   PubMed Web of Science ®Google Scholar
• Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, etal. Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis. 2005; 192: 510–9.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, etal. A prospective nested case-control study of dengue in infants: rethinking and refining the antibodydependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009; 6: 1000171.
   PubMed Web of Science ®Google Scholar
• Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, etal. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004; 189: 990–1000.
   Web of Science ®Google Scholar
• Halstead SB. Dengue. Lancet. 2007; 370: 1644–52.
   PubMed Web of Science ®Google Scholar
• Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, Gonzalez D, etal. Dengue hemorrhagic fever caused by sequential dengue 1–3 virus infections over a long time interval: havana epidemic, 2001–2002. Am J Trop Med Hyg. 2006; 75: 1113–7.
   PubMed Web of Science ®Google Scholar
• Westaway EG, Blok J, Gubler DJ, Kuno G. Taxonomy an evolutionary relationships of flaviviruses. Dengue an dengue hemorrhagic fever. 1997; New York: CABI. 147–74.
   Google Scholar
• Barnes WJ, Rosen L. Fatal hemorrhagic disease and shock associated with primary dengue infection on a Pacific island. Am J Trop Med Hyg. 1974; 23: 495–506.
   PubMed Web of Science ®Google Scholar
• Rosen L. The emperor's new lothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am J Trop Med Hyg. 1977; 26: 337–43.
   PubMed Web of Science ®Google Scholar
• Gubler DJ, Suharyono W, Lubis I, Eram S, Gunarso S. Epidemic dengue 3 in central Java, associated with low viremia in man. Am J Trop Med Hyg. 1981; 30: 1094–9.
   PubMed Web of Science ®Google Scholar
• Anderson JR, Rico-Hesse R. Aedes aegypti vectorial capacity is determined by the infecting genotype of dengue virus. Am J Trop Med Hyg. 2006; 75: 886–92.
   Web of Science ®Google Scholar
• Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology. 1990; 174: 479–93.
   PubMed Web of Science ®Google Scholar
• Messer WB, Vitarana UT, Sivananthan K, Elvtigala J, Preethimala LD, Ramesh R, etal. Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. Am J Trop Med Hyg. 2002; 66: 765–73.
   Web of Science ®Google Scholar
• Kanakaratne N, Wahala WM, Messer WB, Tissera HA, Shahani A, Abeysinghe N, etal. Severe dengue epidemics in Sri Lanka, 2003–2006. Emerg Infect Dis. 2009; 15: 192–9.
   PubMed Web of Science ®Google Scholar
• Hanley KA, Nelson JT, Schirtzinger EE, Whitehead SS, Hanson CT. Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus. BMC Ecol. 2008; 8: 1.
   Google Scholar
• Vasilakis N, Shell EJ, Fokam EB, Mason PW, Hanley KA, Estes DM, etal. Potential of ancestral sylvatic dengue-2 viruses to re-emerge. Virology. 2007; 358: 402–12.
   PubMed Web of Science ®Google Scholar
• Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, de C, etal. Dengue virus structural differences that correlate with pathogenesis. J Virol. 1999; 73: 4738–47.
   PubMed Web of Science ®Google Scholar
• Kochel TJ, Watts DM, Gozalo AS, Ewing DF, Porter KR, Russell KL. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J Infect Dis. 2005; 191: 1000–4.
   PubMed Web of Science ®Google Scholar
• Bhamarapravati N. Hemostatic defects in dengue hemorrhagic fever. Rev Infect Dis. 1989; 11(Suppl 4): S826–9.
   PubMedGoogle Scholar
• Hotta S. Propagation of dengue virus in tissue culture. Acta Trop. 1969; 16: 108–50.
   Google Scholar
• Bhamarapravati N, Toochinda P, Boonyapaknavik V. Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. Am J Trop Med Parasitol. 1967; 61: 500–10.
   PubMed Web of Science ®Google Scholar
• Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Han SW, etal. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol. 2001; 166: 1499–506.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol. 2001; 75: 3501–8.
   PubMed Web of Science ®Google Scholar
• Marovich M, Grouard-Vogel G, Louder M, Eller M, Sun W, Wu SJ, etal. Human dendritic cells as targets of dengue virus infection. J Investig Dermatol Symp Proc. 2001; 6: 219–24.
   PubMedGoogle Scholar
• Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, etal. Human skin Langerhans cells are targets of dengue virus infection. Nat Med. 2000; 6: 816–20.
   PubMed Web of Science ®Google Scholar
• Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J Invest Dermatol. 2000; 114: 560–8.
   PubMed Web of Science ®Google Scholar
• Boonpucknavig S, Boonpucknavig V, Bhamarapravati N, Nimmannitya S. Immunofluorescence study of skin rash in patients with dengue hemorrhagic fever. Arch Pathol Lab Med. 1979; 103(9): 463–6.
   PubMed Web of Science ®Google Scholar
• Sahaphong S, Riengrojpitak S, Bhamarapravati N, Chirachariyavej T. Electron microscopic study of the vascular endothelial cell in dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health. 1980; 11: 194–_204.
   PubMedGoogle Scholar
• Scott RM, Nisalak A, Cheamudon U, Seridhoranakul S, Nimmannitya S. Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever. J Infect Dis. 1980; 141: 1–6.
   Web of Science ®Google Scholar
• Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis. 2004; 189: 1411–8.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol. 2003; 77: 2578–86.
   PubMed Web of Science ®Google Scholar
• Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol. 2002; 267: 171–94.
   PubMed Web of Science ®Google Scholar
• Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis. 2001; 7: 714–21.
   PubMed Web of Science ®Google Scholar
• Xiao SY, Zhang H, Guzman H, Tesh RB. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis. 2001; 183: 1437–44.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Vargas MJ, Wanionek K, Hammond SN, Gordon A, Rocha C, etal. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology. 2008; 376: 429–35.
   PubMed Web of Science ®Google Scholar
• Marchette NJ, Halstead SB, Falkler WA Jr, Stenhouse A, Nash D. Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J Infect Dis. 1973; 128: 23–30.
   Web of Science ®Google Scholar
• Bhoopat L, Bhamarapravati N, Attasiri C, Yoksarn S, Chaiwun B, Khunamornpong S, etal. Immunohistochemical characterization of a new monoclonal antibody reactive with dengue virus-infected cells in frozen tissue using immunoperoxidase technique. Asian Pac J Allergy Immunol. 1996; 14: 107–13.
   Web of Science ®Google Scholar
• Couvelard A, Marianneau P, Bedel C, Drouet MT, Vachon F, Henin D, etal. Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Hum Pathol. 1999; 30: 1106–10.
   PubMed Web of Science ®Google Scholar
• Huerre MR, Lan NT, Marianneau P, Hue NB, Khun H, Hung NT, etal. Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children. Virchows Arch. 2001; 438: 107–15.
   PubMed Web of Science ®Google Scholar
• Miagostovich MP, Ramos RG, Nicol AF, Nogueira RM, Cuzzi-Maya T, Oliveira AV, etal. Retrospective study on dengue fatal cases. Clin Neuropathol. 1997; 16: 204–8.
   PubMed Web of Science ®Google Scholar
• Hall WC, Crowell TP, Watts DM, Barros VL, Kruger H, Pinheiro F, etal. Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. Am J Trop Med Hyg. 1991; 45: 408–17.
   PubMed Web of Science ®Google Scholar
• Ramos C, Sanchez G, Pando RH, Baquera J, Hernandez D, Mota J, etal. Dengue virus in the brain of a fatal case of hemorrhagic dengue fever. J Neurovirol. 1998; 4: 465–8.
   PubMed Web of Science ®Google Scholar
• Andrews BS, Theofilopoulos AN, Peters CJ, Loskutoff DJ, Brandt WE, Dixon FJ, etal. Replication of dengue and junin viruses in cultured rabbit and human endothelial cells. Infect Immun. 1978; 20: 776–81.
   PubMed Web of Science ®Google Scholar
• Balsitis SJ, Coloma J, Castro G, Alava A, Flores D, McKerrow JH, etal. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg. 2009; 80: 416–24.
   PubMed Web of Science ®Google Scholar
• Wang L, Chen RF, Liu JW, Lee IK, Lee CP, Kuo HC, etal. DC-SIGN (CD209) Promoter -336 A/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. PLoS Negl Trop Dis. 2011; 5: e934.
   PubMed Web of Science ®Google Scholar
• Avirutnan P, Zhang L, Punyadee N, Manuyakorn A, Puttikhunt C, Kasinrerk W, etal. Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog. 2007; 3: e183.
   PubMed Web of Science ®Google Scholar
• Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine. 2011; 29: 7221–8.
   PubMed Web of Science ®Google Scholar
• Valdes K, Alvarez M, Pupo M, Vazquez S, Rodriguez R, Guzman MG. Human dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol. 2000; 7: 856–7.
   PubMedGoogle Scholar
• Churdboonchart V, Bhamarapravati N, Peampramprecha S, Sirinavin S. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg. 1991; 44: 481–93.
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology. 1998; 246: 317–28.
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, etal. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010; 84: 9227–39.
   PubMed Web of Science ®Google Scholar
• Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, etal. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008; 15: 312–7.
   PubMed Web of Science ®Google Scholar
• Kaufmann B, Nybakken GE, Chipman PR, Zhang W, Diamond MS, Fremont DH, etal. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A. 2006; 103: 12400–4.
   PubMed Web of Science ®Google Scholar
• Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, etal. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 2009; 28: 3269–76.
   Web of Science ®Google Scholar
• Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, etal. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008; 82: 6631–43.
   PubMed Web of Science ®Google Scholar
• Lin B, Parrish CR, Murray JM, Wright PJ. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology. 1994; 202: 885–90.
   PubMed Web of Science ®Google Scholar
• Lok SM, Ng ML, Aaskov J. Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. J Med Virol. 2001; 65: 315–23.
   PubMed Web of Science ®Google Scholar
• Wang WK, Lin SR, Lee CM, King CC, Chang SC. Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies. J Virol. 2002; 76: 4662–5.
   PubMed Web of Science ®Google Scholar
• Wang WK, Sung TL, Lee CN, Lin TY, King CC. Sequence diversity of the capsid gene and the nonstructural gene NS2B of dengue-3 virus in vivo. Virology. 2002; 303: 181–91.
   Web of Science ®Google Scholar
• Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH, Pierson TC, etal. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe. 2007; 2: 417–26.
   PubMed Web of Science ®Google Scholar
• Bokisch VA, Top FH Jr, Russell PK, Dixon FJ, Muller- Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med. 1973; 289: 996–1000.
   PubMed Web of Science ®Google Scholar
• Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J Trop Med Public Health. 1987; 18: 316–20.
   PubMedGoogle Scholar
• Mentor NA, Kurane I. Dengue virus infection of human T lymphocytes. Acta Virol. 1997; 41: 175–6.
   Web of Science ®Google Scholar
• Gagnon SJ, Ennis FA, Rothman AL. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol. 1999; 73: 3623–9.
   PubMed Web of Science ®Google Scholar
• Mangada MM, Ennis FA, Rothman AL. Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining. J Immunol Methods. 2004; 284: 89–97.
   PubMed Web of Science ®Google Scholar
• Bashyam HS, Green S, Rothman AL. Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol. 2006; 176: 2817–24.
   PubMed Web of Science ®Google Scholar
• Imrie A, Meeks J, Gurary A, Sukhbataar M, Kitsutani P, Effler P, etal. Differential functional avidity of dengue virusspecific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol. 2007; 81: 10081–91.
   PubMed Web of Science ®Google Scholar
• Dong T, Moran E, Vinh Chau N, Simmons C, Luhn K, Peng Y, etal. High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS One. 2007; 2: e1192.
   Web of Science ®Google Scholar
• Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, etal. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A. 2010; 107: 16922–7.
   PubMed Web of Science ®Google Scholar
• An J, Zhou DS, Zhang JL, Morida H, Wang JL, Yasui K. Dengue-specific CD8+ T cells have both protective and pathogenic roles in dengue virus infection. Immunol Lett. 2004; 95: 167–74.
   PubMed Web of Science ®Google Scholar
• Luhn K, Simmons CP, Moran E, Dung NT, Chau TN, Quyen NT, etal. Increased frequencies of CD4+ CD25(high) regulatory T cells in acute dengue infection. J Exp Med. 2007; 204: 979–85.
   PubMed Web of Science ®Google Scholar
• Kurane I, Innis BL, Nimmannitya S, Nisalak A, Rothman AL, Livingston PG, etal. Human immune responses to dengue viruses. Southeast Asian J Trop Med Public Health. 1990; 21: 658–62.
   PubMedGoogle Scholar
• Rothman AL, Ennis FA. Immunopathogenesis of dengue hemorrhagic fever. Virology. 1999; 257: 1–6.
   PubMed Web of Science ®Google Scholar
• Zivna I, Green S, Vaughn DW, Kalayanarooj S, Stephens HA, Chandanayingyong D, etal. T cell responses to an HLA-B*07- restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol. 2002; 168: 5959–65.
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, etal. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003; 9: 921–7.
   PubMed Web of Science ®Google Scholar
• Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. 2005; 175: 2676–83.
   PubMed Web of Science ®Google Scholar
• Valdes L, Guzman MG, Kouri G, Delgado J, Carbonell I, Cabrera MV, etal. Epidemiology of dengue and hemorrhagic dengue in Santiago, Cuba 1997. Rev Panam Salud Publica. 1999; 6: 16–25.
   PubMedGoogle Scholar
• Halstead SB, Rojanasuphot S, Sangkawibha N. Original antigenic sin in dengue. Am J Trop Med Hyg. 1983; 32: 154–6.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Alvarez M, Rodriguez R, Rosario D, Vazquez S, Vald S, etal. Fatal dengue hemorrhagic fever in Cuba, 1997. Int J Infect Dis. 1999; 3: 130–5.
   PubMedGoogle Scholar
• Pelaez O, Guzman MG, Kouri G, Perez R, San Martin JL, Vazquez S, etal. Dengue 3 epidemic, Havana, 2001. Emerg Infect Dis. 2004; 10: 719–22.
   Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4: 499–511.
   PubMed Web of Science ®Google Scholar
• Bowie AG, Haga IR. The role of toll-like receptors in the host response to viruses. Mol Immunol. 2005; 42: 859–67.
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell. 2006; 22: 561–9.
   PubMed Web of Science ®Google Scholar
• Severa M, Fitzgerald KA. TLR-mediated activation of type I IFN during antiviral immune responses: fighting the battle to win the war. Curr Top Microbiol Immunol. 2007; 316: 167–92.
   PubMed Web of Science ®Google Scholar
• Anderson R. Manipulation of cell surface macromolecules by flaviviruses. Adv Virus Res. 2003; 59: 229–74.
   Web of Science ®Google Scholar
• Carr JM, Hocking H, Bunting K, Wright PJ, Davidson A, Gamble J, etal. Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers. J Med Virol. 2003; 69: 521–8.
   Web of Science ®Google Scholar
• Espina LM, Valero NJ, Hernandez JM, Mosquera JA. Increased apoptosis and expression of tumor necrosis factoralpha caused by infection of cultured human monocytes with dengue virus. Am J Trop Med Hyg. 2003; 68: 48–53.
   PubMed Web of Science ®Google Scholar
• Charnsilpa W, Takhampunya R, Endy TP, Mammen MP Jr, Libraty DH, Ubol S. Nitric oxide radical suppresses replication of wild-type dengue 2 viruses in vitro. J Med Virol. 2005; 77: 89–95.
   PubMed Web of Science ®Google Scholar
• Neves-Souza PC, Azeredo EL, Zagne SM, Valls-de-Souza R, Reis SR, Cerqueira DI, etal. Inducible nitric oxide synthase (iNOS) expression in monocytes during acute Dengue Fever in patients and during in vitro infection. BMC Infect Dis. 2005; 5: 64.
   Web of Science ®Google Scholar
• Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol. 2003; 111(2 Suppl): S460–75.
   PubMedGoogle Scholar
• Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol. 2008; 53: 287–99.
   PubMedGoogle Scholar
• Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, etal. Elevated plasma interleukin- 10 levels in acute dengue correlate with disease severity. J Med Virol. 1999; 59: 329–34.
   PubMed Web of Science ®Google Scholar
• Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, etal. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest. 1991; 88: 1473–80.
   PubMed Web of Science ®Google Scholar
• Hober D, Poli L, Roblin B, Gestas P, Chungue E, Granic G, etal. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg. 1993; 48: 324–31.
   PubMed Web of Science ®Google Scholar
• Iyngkaran N, Yadav M, Sinniah M. Augmented inflammatory cytokines in primary dengue infection progressing to shock. Singap Med J. 1995; 36: 218–21.
   Google Scholar
• Juffrie M, Meer GM, Hack CE, Haasnoot K, Sutaryo AJ, Veerman. Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. Am J Trop Med Hyg. 2001; 65: 70–5.
   Web of Science ®Google Scholar
• Talavera D, Castillo AM, Dominguez MC, Gutierrez AE, Meza I. IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J Gen Virol. 2004; 85: 1801–13.
   PubMed Web of Science ®Google Scholar
• Hober D, Shen L, Benyoucef S, De Groote D, Deubel V, Wattre P. Enhanced TNF alpha production by monocytic-like cells exposed to dengue virus antigens. Immunol Lett. 1996; 53: 115–20.
   Web of Science ®Google Scholar
• Bethell DB, Flobbe K, Cao XT, Day NP, Pham TP, Buurman WA, etal. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis. 1998; 177: 778–82.
   PubMed Web of Science ®Google Scholar
• Sierra B, Perez AB, Vogt K, Garcia G, Schmolke K, Aguirre E, etal. MCP-1 and MIP-1alpha expression in a model resembling early immune response to dengue. Cytokine. 2010; 52: 175–83.
   Web of Science ®Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996; 17: 138–46.
   PubMedGoogle Scholar
• Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virusinduced hemorrhage. J Virol. 2007; 81: 5518–26.
   PubMed Web of Science ®Google Scholar
• Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC. Immunopathogenesis of dengue virus infection. J Biomed Sci. 2001; 8: 377–88.
   PubMed Web of Science ®Google Scholar
• Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009; 22: 564–81.
   PubMed Web of Science ®Google Scholar
• Kallmann BA, Hummel V, Lindenlaub T, Ruprecht K, Toyka KV, Rieckmann P. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain. 2000; 123: 687–_97.
   PubMed Web of Science ®Google Scholar
• Madan B, Singh I, Kumar A, Prasad AK, Raj HG, Parmar VS, etal. Xanthones as inhibitors of microsomal lipid peroxidation and TNF-alpha induced ICAM-1 expression on human umbilical vein endothelial cells (HUVECs). Bioorg Med Chem. 2002; 10: 3431–6.
   PubMed Web of Science ®Google Scholar
• Dagia NM, Goetz DJ. A proteasome inhibitor reduces concurrent, sequential, and long-term IL-1 beta- and TNF-alpha-induced ECAM expression and adhesion. Am J Physiol Cell Physiol. 2003; 285: C813–22.
   Web of Science ®Google Scholar
• Javaid K, Rahman A, Anwar KN, Frey RS, Minshall RD, Malik AB. Tumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1. Circ Res. 2003; 92: 1089–97.
   PubMed Web of Science ®Google Scholar
• Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol. 1997; 71: 4226–32.
   PubMed Web of Science ®Google Scholar
• Weaver KA, H.a.S.C . Frontiers in dengue virus research. Chapter 6. 2010; Norfolk, UK: Caister Academic Press.
   Google Scholar
• Tuiskunen A, Monteil V, Plumet S, Boubis L, Wahlstrom M, Duong V, etal. Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Arch Virol. 2011; 156: 2023–32.
   Web of Science ®Google Scholar
• Barreto DF, etal. Histopathological and ultrastructural aspects of mice lungs experimentally infected with dengue virus serotype 2. Mem Inst Oswaldo Cruz. 2007; 102: 175–82.
   PubMed Web of Science ®Google Scholar
• Paes MV, Pinhao AT, Barreto DF, Costa SM, Oliveira MP, Nogueira AC, et al. Liver injury and viremia in mice infected with dengue-2 virus. Virology 2005; 338: 236–46..
   Google Scholar
• Huang KJ, Li SY, Chen SC, Liu HS, Lin YS, Yeh TM, etal. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol. 2000; 81: 2177–82.
   PubMed Web of Science ®Google Scholar
• Tuiskunen A, Wahlstrom M, Bergstrom J, Buchy P, Leparc-Goffart I, Lundkvist A. Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Virol J. 2011; 8: 398.
   PubMed Web of Science ®Google Scholar
• Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol. 2003; 35: 33–42.
   PubMedGoogle Scholar
• Zulueta A, Martin J, Hermida L, Alvarez M, Valdes I, Prado I, etal. Amino acid changes in the recombinant dengue 3 envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res. 2006; 121: 65–73.
   PubMed Web of Science ®Google Scholar
• An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K. Development of a novel mouse model for dengue virus infection. Virology. 1999; 263: 70–7.
   PubMed Web of Science ®Google Scholar
• Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, etal. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J Virol. 1998; 72: 9729–37.
   PubMed Web of Science ®Google Scholar
• Blaney JE Jr, Johnson DH, Manipon GG, Firestone CY, Hanson CT, Murphy BR, etal. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology. 2002; 300: 125–39.
   PubMed Web of Science ®Google Scholar
• Bente DA, Melkus MW, Garcia JV, Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J Virol. 2005; 79: 13797–9.
   PubMed Web of Science ®Google Scholar
• Kuruvilla JG, Troyer RM, Devi S, Akkina R. Dengue virus infection and immune response in humanized RAG2(-/-) gamma(c)(-/-) (RAG-hu) mice. Virology. 2007; 369: 143–52.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, etal. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995; 154: 180–91.
   PubMed Web of Science ®Google Scholar
• Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM, etal. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity. 1995; 2: 223–38.
   PubMed Web of Science ®Google Scholar
• DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1995; 92: 377–81.
   PubMed Web of Science ®Google Scholar
• Ohbo K, Suda T, Hashiyama M, Mantani A, Ikebe M, Miyakawa K, etal. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood. 1996; 87: 956–67.
   PubMed Web of Science ®Google Scholar
• Ifversen P, Borrebaeck CA. SCID-hu-PBL: a model for making human antibodies?. Semin Immunol. 1996; 8: 243–8.
   PubMedGoogle Scholar
• Murphy WJ, Taub DD, Longo DL. The huPBL-SCID mouse as a means to examine human immune function in vivo. Semin Immunol. 1996; 8: 233–41.
   PubMedGoogle Scholar
• Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, etal. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174: 6477–89.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, etal. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005; 106: 1565–73.
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol. 1999; 73: 783–6.
   PubMed Web of Science ®Google Scholar
• Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol. 2004; 78: 2701–10.
   PubMed Web of Science ®Google Scholar
• Kyle JL, Beatty PR, Harris E. Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis. 2007; 195: 1808–17.
   Web of Science ®Google Scholar
• Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol. 2003; 77: 11436–47.
   PubMed Web of Science ®Google Scholar
• Lee E, Wright PJ, Davidson A, Lobigs M. Virulence attenuation of dengue virus due to augmented glycosaminoglycanbinding affinity and restriction in extraneural dissemination. J Gen Virol. 2006; 87: 2791–801.
   Web of Science ®Google Scholar
• Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. 2007; 195: 665–74.
   PubMed Web of Science ®Google Scholar
• Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol. 2006; 80: 10208–17.
   PubMed Web of Science ®Google Scholar
• Stein DA, Huang CY, Silengo S, Amantana A, Crumley S, Blouch RE, etal. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J Antimicrob Chemother. 2008; 62: 555–65.
   Web of Science ®Google Scholar
• Kyle JL, Balsitis SJ, Zhang L, Beatty PR, Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology. 2008; 380: 296–303.
   PubMed Web of Science ®Google Scholar
• Prestwood TR, Prigozhin DM, Sharar KL, Zellweger RM, Shresta S. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol. 2008; 82: 8411–21.
   PubMed Web of Science ®Google Scholar